2 m 2			•					She	et l of 2	
Form PTO-1449					Docket Number 532212002000 Application Number 10/664,263					
INFORMATION DISCLOSURE CITATION OF EN AN APPLICATION					Applicant Thomas L. CANTOR					
					Filing Date September 16,	Group Art Unit: 1641				
JAN 2 6 2004										
JAN 2) ZUU4 _{[1}	,		Mailing Date January 22, 2004						
JAN 2 6 2004 U.S. PATENT					T DOCUMENTS					
Examiner	Ref.	Date	Document No.	Ī	Name	Class	Subclass	Filing Date If		
Initials	No.				,			Approj		
	1.	01/2002	20020009740	Ka	ddurah-Daouk et al.	435	6			
	2.	02/2003	20030040027	Rit	ter et al.	435	7.21			
	•		FOREIGN	PAT	ENT DOCUMENT	TS.				
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	Translation YES NO		
Examiner Ref. Title Initials No.					OCUMENTS					
· .	3.									
	 Dybedal et al., Blood 86(3):949-57 (1995) Eckardt et al., Nephrol. Dial. Transplant 18:865-69 (2003) EPOGEN® (Epoetin alfa) (available on the internet at www.renaladvances.com/PDF/EpogenPI.pdf) pro insert 									
									oduct	
	7. Eschbach et al., N. Engl. J. Med. 316:73-78 (1987)									
8. Goodman et al., Adv. Ren. Replace Ther. 2002 Jul;9(3):200										
9. Hillman, Hematopoietic Agents - Growth Factors, Minerals, and Vitamins, in THE PHARMACOLOG OF THERAPEUTICS 1312-15 (JG Hardman, et al. eds., 9th ed. 1996)							COLOGICAL	BASIS		
	10. J	Jacobs et al., Nature 313:806 (1985)								
Johnson & Johnson Press Release "Summary of PRCA Case Rep www.jnj_com/news/jnj_news/1021024_095632.htm)							14, 2003 (availa	able at		
	12.	Kifor et al., J. Clin. Endocrinology & Metabolism 88(1):60-72 (2003)								
	13. 🗸	Lin et al., Proc. Natl. Acad. Sci. USA 82:7580 (1985)								
	14.	Parthemore et al., J. Clin. Endocrinol. Metab. 1978 Aug;47(2):284-9								
	15.	Ponnappan e	et al., Hybridoma 19(5):	61 (2000)						
		1								
EXAMINER:					DATE CONSIDERED:					
			nsidered, whether or not the				a line through the	citation if no	ot in	

conformance and not considered. Include a copy of this form with next communication to applicant.